221 related articles for article (PubMed ID: 15144730)
1. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
2. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu XY; Kato Y; Sugiyama Y
Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
[TBL] [Abstract][Full Text] [Related]
3. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
4. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
5. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
6. Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
Arimori K; Kuroki N; Kumamoto A; Tanoue N; Nakano M; Kumazawa E; Tohgo A; Kikuchi M
Pharm Res; 2001 Jun; 18(6):814-22. PubMed ID: 11474786
[TBL] [Abstract][Full Text] [Related]
7. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
11. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
[TBL] [Abstract][Full Text] [Related]
14. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
16. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072
[TBL] [Abstract][Full Text] [Related]
17. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.
Scott DO; Bindra DS; Sutton SC; Stella VJ
Drug Metab Dispos; 1994; 22(3):438-42. PubMed ID: 8070321
[TBL] [Abstract][Full Text] [Related]
18. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
[TBL] [Abstract][Full Text] [Related]
19. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
